Rheumatoid Arthritis Treatment Market Global Growth By 2026 | Industry Analysis by Size, Trends, Competitor Strategy, High Emerging, Sales Revenue, Competitive Landscape, Opportunity and Challenges

Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women.  Rheumatoid can affect any joint, small joints in hand and feet tend to be affected the most. Treatments are available for rheumatoid arthritis help in relieving symptoms and improve the joint function. RA treatment usually involves the integration of patient education, exercise, medications, and surgery (occasionally).

Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-sample/166

The rheumatoid arthritis treatment market can be analyzed based on the drug type.

By Drug Type

• Biological drugs
  • Monoclonal antibodies
• Non-Biologicals
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Analgesics
  • Disease-modifying anti-rheumatic drugs (DMARDs)
    • IL-6 inhibitors
    • TNF inhibitors

Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/166

NSAIDs and corticosteroids are also first-line fast-acting therapeutic drugs. Acetylsalicylate, naproxen, ibuprofen, etodolac, and diclofenac are the NSAIDs usually prescribed as first-line drugs for RA for reducing inflammation, and pain. Corticosteroid medications can be given orally to reduce inflammation and restore joint mobility and function. The global rheumatoid arthritis treatment industry is expected to be driven considerably in the near future by DMARDs that form second line slow-acting therapeutic drugs. The longer therapeutic regimen with these drugs increases the cost of therapy and also promotes remission of joint destruction and deformity. Methotrexate is the most commonly prescribed second-line drug for RA and hence, occupies a major share in the respective segment of the global rheumatoid arthritis treatment market.

FDA approved biologic drugs include rituximab (Rituxan, MabThera), abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel), certolizumab (Cimzia), anakinra (Kineret), infliximab (Remicade), golimumab (Simponi), and tocilizumab (Actemra). Besides these approved drugs, biosimilars in the pipeline would fuel the rheumatoid arthritis treatment market growth in the near future.

Key statistics pertaining to the global rheumatoid arthritis treatment market:

Over time, there is damage to cartilage and mobility function of the affected joint in rheumatoid arthritis patients.

• Affects nearly 1.3 million U.S. population (RheumatoidArthritis.org)
• Most common in the age group of 30-60 years
• The global prevalence varies in the range of 0.3% to 1% (World Health Organization)
• The average annual cost of treatment may go up to the US $20,000 (RheumatoidArthritis.org)
• According to the Arthritis Foundation, people with RA lose more workdays compared to those affected by any other medical condition
• According to a Harvard University study published in the Journal of Global Health (2017), the prevalence of rheumatoid arthritis in Southeast Asian countries was 0.4%, 0.42 in western Pacific region, and 0.37% in eastern Mediterranean countries

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/rheumatoid-arthritis-treatment-market-166

A plethora of research work to develop effective treatment therapies in the global rheumatoid arthritis treatment market

The development of newer therapies is projected to fuel the growth of the rheumatoid arthritis treatment market in developed nations.  The Chinese FDA recently approved Xeljanz for RZ treatment (2017). The product is awaiting approval from the EU. Among the Asian countries, India, China, Pakistan, and Bangladesh had major prevailing rheumatoid arthritis patients as per WHO–ILAR COPCORD (International League of Associations for Rheumatology) (Community Oriented Program for Control of Rheumatic Diseases) studies (2015). Some of the products in the pipeline include:

Antibodies that target collagen II, an important protein in joint cartilage (Researchers at the Department of Immunology, Genetics and Pathology, Uppsala University, Sweden)

Stem cell I.V. therapy developed by Mesoblast Ltd. to treat RA patients unresponsive to TNF drugs (phase 2 trials)

More of such developments by the market players will be a significant contributor towards the growth of the global rheumatoid arthritis treatment industry.

Some of the major players in the global rheumatoid arthritis treatment market are Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,

Request to download and view full ToC: https://www.coherentmarketinsights.com/ongoing-insight/toc/166

Key Developments

Major players in the market are focused on gaining product approvals to expand their product portfolio. For instance, in August 2019, AbbVie, a biopharmaceutical company, received the U.S. approval for RINVOQ (upadacitinib), an oral JAK Inhibitor for the treatment of moderate to severe rheumatoid arthritis.

Major institutes and universities are increasing research and development for the development of novel therapies and technologies for the treatment of rheumatoid arthritis. For instance, in August 2019, researchers from the Kaohsiung Medical University, in the paper ‘Next-Generation Sequencing Profiles of the Methylome and Transcriptome in Peripheral Blood Mononuclear Cells of Rheumatoid Arthritis’ published in the journal MDPI Journal of Clinical Medicine, revealed a map to the peripheral blood mononuclear cells methylome and found that rheumatoid arthritis genetically associated genes and their interacting targets probably demonstrate differential methylation and differential expression than non-rheumatoid arthritis genetically associated genes.

Moreover, in August 2019, a team of researchers from the University of Groningen and the University of Exeter Medical School suggested that Gal-9, a pleiotropic immunomodulatory protein probably promotes immunopathology in rheumatoid arthritis through its stimulatory effect on granulocytes.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837